IP Library Granted Patent US 10,173,989
Granted Patent B2
US 10,173,989 · App. 15/713,671 · Granted Jan 8, 2019

1,2,4-oxadiazole derivatives as immunomodulators

Inventors: Pottayil Govindan Nair Sasikumar (Bangalore, IN); Muralidhara Ramachandra (Bangalore, IN); Seetharamaiah Setty Sudarshan Naremaddepalli (Bangalore, IN)
Assignee: Aurigene Discovery Technologies Limited
C07D271/06A61K31/395A61K31/4245A61K31/433A61K45/06C07D273/00C07D273/08Y02A50/385Y02A50/406Y02A50/409Y02A50/411Y02A50/414Y02A50/463Y02A50/465Y02A50/467Y02A50/469Y02A50/471Y02A50/473Y02A50/478Y02A50/481
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,173,989
App. No.
15/713,671
Granted
Jan 8, 2019
Kind
B2
Abstract

The present invention relates to synthetic methods for 1,2,4-oxadiazole compounds. The general synthetic scheme is: R 1 represents −CH 2 O t Bu or −CH(CH 3 )O t Bu, R 3 represents −CH 2 C(O)NHCPh 3 , −CH 2 CH 2 C(O)NHCPh 3 , −CH 2 C(O)O t Bu, or −CH 2 CH 2 C(O)O t Bu, and Aaa is an amino acid residue selected from Thr and Ser; wherein the C-terminus thereof is esterified, and wherein the hydroxy moiety of the side chain of Thr or Ser is substituted with tbutyl; the base is triethylamine; and the solvent is tetrahydrofuran.

Claims (17)

1. A method of making a compound according to the following scheme:

wherein:

R 1 represents —CH 2 O t Bu or —CH(CH 3 )O t Bu;

Aaa is an amino acid residue selected from Thr and Ser; wherein the C-terminus thereof is esterified, and wherein the hydroxy moiety of the side chain of Thr or Ser is substituted with t-butyl;

R 3 represents —CH 2 C(O)NHCPh 3 , —CH 2 CH 2 C(O)NHCPh 3 , —CH 2 C(O)O t Bu, or —CH 2 CH 2 C(O)O t Bu;

the base is triethylamine; and

the solvent is tetrahydrofuran.

2. The method of claim 1 , wherein:

Aaa is an amino acid residue selected from Thr and Ser; wherein the C-terminus thereof is esterified, and wherein the hydroxy moiety of the side chain of Thr or Ser is substituted with t-butyl;

R 1 represents —CH 2 O t Bu or —CH(CH 3 )O t Bu; and

R 3 represents (a) —CH 2 C(O)NHCPh 3 or —CH 2 CH 2 C(O)NHCPh 3 or (b) —CH 2 C(O)O t Bu, or —CH 2 CH 2 C(O)O t Bu—;

said method further comprising the step of contacting the compound of formula

with trifluoroacetic acid, to form a compound of formula

wherein:

Aaa′ is an amino acid residue selected from Thr and Ser; wherein the C-terminus thereof is a free terminus;

R 1a represents CH 2 OH or —CH(CH 3 )OH; and

R 3a represents (a) —CH 2 C(O)NH 2 or —CH 2 CH 2 C(O)NH 2 or (b) —CH 2 C(O)OH or —CH 2 CH 2 C(O)OH.

Assignments (1)
CHANGE OF NAME Recorded May 16, 2023
From: AURIGENE DISCOVERY TECHNOLOGIES LIMITED
To: AURIGENE ONCOLOGY LIMITED
Reel/Frame 063654/0411 →
Priority Claims (1)
IN 4011/CHE/2013 · Sep 6, 2013 · national
Continuity (3)
Continuation 15298539 · Oct 20, 2016
Continuation 14478759 · Sep 5, 2014
Related Publication 20180072689A1 · Mar 15, 2018
Cited By (4)
US 12,187,689 US 12,226,402 US 12,252,475 US 12,643,870